BTK Inhibitors: Future Directions

On-demand Clinical Care Options (CCO) webcast with experts’ review of data informing optimal management of relapsed/refractory myeloma

Shaji K. Kumar, MD
Program Director Suzanne Lentzsch, MD, PhD Saad Z. Usmani, MD, MBA, FACP Physicians: maximum of 0.75 AMA PRA Category 1 Credits™ Released: March 31, 2021 Expired: March 30, 2022

From Clinical Care Options (CCO), read an expert commentary on how to safely provide CAR T-cell therapy during the COVID-19 pandemic

Caron A. Jacobson, MD Released: March 31, 2021

Free video from Clinical Care Options (CCO) featuring expert discussion of the latest updates in CAR T-cell therapy for hematologic cancers

Renier J. Brentjens, MD, PhD
Program Director Frederick L. Locke, MD Noopur Raje, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Released: March 29, 2021 Expired: March 28, 2022

From Clinical Care Options (CCO), a commentary from 3 myeloma experts on selecting treatment for relapsed/refractory disease

Shaji K. Kumar, MD
Program Director Suzanne Lentzsch, MD, PhD Saad Z. Usmani, MD, MBA, FACP Released: March 29, 2021